Protocol for the Examination of Resection Specimens From Patients With Neuroblastoma

Version: 5.0.0.0  
Protocol Posting Date: September 2023  
CAP Laboratory Accreditation Program Protocol Required Use Date: June 2024

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated resection, or other</td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Description</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Includes pediatric patients with neuroblastoma and related neuroblastic tumors</td>
</tr>
</tbody>
</table>

The following should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy (consider Neuroblastoma Biopsy protocol)</td>
</tr>
</tbody>
</table>

Authors

Jessica L. Davis, MD*; Jason A. Jarzembowski, MD, PhD*; Miguel Reyes-Mugica, MD; Hiroyuki Shimada, MD, PhD; Rochelle Bagatell, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (i.e., secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- **Data element:** followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e., all required elements must be in the synoptic portion of the report in the format defined above.
Summary of Changes
v 5.0.0.0

- Protocol updated for accreditation requirement
Reporting Template

Protocol Posting Date: September 2023
Select a single response unless otherwise indicated.

CASE SUMMARY: (NEUROBLASTOMA: Resection)

EXPERT CONSULTATION

+Expert Consultation (Note A)
___ Pending - Completion of this CAP Cancer Protocol is awaiting expert consultation
___ Completed - This CAP Cancer Protocol or some elements have been performed following expert consultation
___ Not applicable

CLINICAL

Treatment History (Note B)
___ No known preoperative therapy
___ Preoperative therapy given
___ Not specified

Patient Age
___ Less than 18 months
___ Greater than or equal to 18 months and less than 5 years
___ Greater than or equal to 5 years

+Tissue Allocation (Note B) (select all that apply)
___ Formalin fixed paraffin embedded (FFPE)
___ Snap frozen
___ Tissue culture media
___ Other (specify): _________________

SPECIMEN

Procedure
___ Resection
___ Other (specify): _________________
___ Not specified

TUMOR

Tumor Site (Note C)
___ Adrenal / periadrenal
___ Retroperitoneal, nonadrenal
___ Thoracic paraspinal
___ Cervical region
___ Other (specify): _________________
___ Not specified

Tumor Size
___ Greatest dimension in Centimeters (cm): _________________ cm
**+Additional Dimension in Centimeters (cm): ____ x ____ cm**

--- Cannot be determined (explain): ________________________________

--- Histologic Type (Notes D,E)

--- Neuroblastoma

For nodular (composite) ganglioneuroblastomas with more than 1 nodule, degree of differentiation and mitotic-karyorrhectic index (MKI) must be given for each nodule. Please indicate the differentiation and MKI for the least favorable nodule in the checklist below. Classification of additional nodules can be described in the comment.

--- Ganglioneuroblastoma, nodular subtype#

--- Number of Nodules

--- Specify number: __________________________

--- Other (specify): __________________________

--- Cannot be determined (explain): ________________________________

--- Nodular Subtype(s) (repeat for each nodule): _______________________

--- Ganglioneuroblastoma, intermixed subtype

--- Ganglioneuroma

--- Ganglioneuroma, maturing

--- Ganglioneuroma, mature

--- Neuroblastic tumor, unclassifiable

--- Treated neuroblastoma / neuroblastic tumor

--- Cannot be determined (explain): ________________________________

--- Histologic Type Comment: ________________________________

--- Degree of Differentiation (Note F)

Report neuroblastic component if not previously treated

--- Not applicable

--- Undifferentiated

--- Poorly differentiated

--- Differentiating

--- Cannot be determined (explain): ________________________________

--- Mitotic-Karyorrhectic Index (MKI) (Note G)

Report neuroblastic component if not previously treated

--- Not applicable

--- Low (less than 100 per 5000 cells; less than 2%)

--- Intermediate (100-200 per 5000 cells; 2%-4%)

--- High (greater than 200 per 5000 cells; greater than 4%)

--- Cannot be determined (explain): ________________________________

--- Treatment Effect# (Note D)

# Includes maturation / cytodifferentiation, necrosis, fibrosis / stromal overgrowth, among other treatment-related changes

--- Not applicable

--- Not identified

--- Present

--- Percentage of Treatment Effect

--- Specify percentage: __________________________ %

--- Other (specify): ________________________________

--- Cannot be determined

--- Percentage of Therapy-Induced Maturation / Cytodifferentiation

--- Specify percentage: __________________________ %

--- Other (specify): ________________________________
 REGIONAL LYMPH NODES

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
    ___ All regional lymph nodes negative for tumor
    ___ Tumor present in regional lymph node(s)
    Number of Lymph Nodes with Tumor
        ___ Exact number (specify): _________________
        ___ At least (specify): _________________
        ___ Other (specify): _________________
        ___ Cannot be determined (explain): _________________
    Nodal Site(s) with Tumor, if known
        ___ Not known
        ___ Specify site(s): _________________
        ___ Cannot be determined: _________________
        ___ Other (specify): _________________
        ___ Cannot be determined (explain): _________________
    Number of Lymph Nodes Examined
        ___ Exact number (specify): _________________
        ___ At least (specify): _________________
        ___ Other (specify): _________________
        ___ Cannot be determined (explain): _________________

+Regional Lymph Node Comment: _________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable
___ Not applicable
___ Specify site(s): _________________
___ Cannot be determined: _________________

PATHOLOGY CLASSIFICATION

International Neuroblastoma Pathology Classification (INPC) (report if not previously treated) (Note H)
INPC applies to untreated primary tumors and tumors in metastatic sites provided that there is sufficient material to classify histologically. Classification based on limited material (biopsy or incomplete resection) may be subject to sampling error and should be noted, accordingly. Bone marrow biopsy is useful only for evaluation of degree of neuroblastic differentiation, but is not eligible for MKI determination.
___ Not applicable (secondary to previous chemotherapy)
___ Favorable histopathology
    ___ Neuroblastoma, poorly differentiated subtype, low or intermediate MKI, less than 18 months old
    ___ Neuroblastoma, differentiating subtype, intermediate MKI, less than 18 months old
    ___ Neuroblastoma, differentiating subtype, low MKI, less than 5 years old
___ Ganglioneuroblastoma, nodular, poorly differentiated subtype, low or intermediate MKI, less than 18 months old
___ Ganglioneuroblastoma, nodular, differentiating subtype, intermediate MKI, less than 18 months old
___ Ganglioneuroblastoma, nodular, differentiating subtype, low MKI, less than 5 years old
___ Ganglioneuroblastoma, intermixed, any age
___ Ganglioneuroma, any age
___ Unfavorable histopathology
___ Neuroblastoma, undifferentiated subtype, any MKI, any age
___ Neuroblastoma, poorly differentiated subtype, high MKI, any age
___ Neuroblastoma, poorly differentiated subtype, low or intermediate MKI, greater than 18 months old
___ Neuroblastoma, differentiating subtype, high MKI, any age
___ Neuroblastoma, differentiating subtype, intermediate MKI, greater than or equal to 18 months old
___ Neuroblastoma, differentiating subtype, low MKI, greater than 5 years old
___ Ganglioneuroblastoma, nodular, undifferentiated subtype, any MKI, any age
___ Ganglioneuroblastoma, nodular, poorly differentiated subtype, high MKI, any age
___ Ganglioneuroblastoma, nodular, poorly differentiated subtype, low or intermediate MKI, greater than 18 months old
___ Ganglioneuroblastoma, nodular, differentiating subtype, intermediate MKI, greater than 18 months old
___ Ganglioneuroblastoma, nodular, differentiating subtype, high MKI, any age
___ Ganglioneuroblastoma, nodular, differentiating subtype, low MKI, greater than 5 years old
___ Cannot be determined (explain): ___________________

ADDITIONAL FINDINGS

+Additional Findings (specify) (Notes I, J): __________________

SPECIAL STUDIES (Notes K, L)

MYCN Amplification Status (for all tumors except ganglioneuroma or post-therapy resection specimens) (Note L)
Results of MYCN amplification information may not be available to the pathologist at the time of the report.
___ Not applicable (secondary to previous chemotherapy)
___ Not amplified
___ Amplified: __________________
___ Gain: __________________
___ Cannot be determined: __________________
___ Pending

+Molecular Genetic Studies (Note L) (select all that apply)
___ Not performed
___ Pending
___ Segmental chromosomal aberration analysis (e.g., 1p deletion, 11q deletion, and / or 17q gain)
   (specify results): __________________
___ ALK mutation / amplification (specify results): __________________
___ Other (specify): __________________
Method for Molecular Genetic Studies (select all that apply)
___ Fluorescent in situ hybridization (FISH)
___ Sequencing (specify type, if known): __________________
___ Microarray
___ Other (specify): __________________

Other Ancillary Studies (specify) (Notes K,L): __________________

COMMENTS

Comment(s): __________________
Explanatory Notes

A. Expert Consultation
Expert consultation is not required. This question has been added to annotate, if so desired, that the case has been sent out for consultation and thus items of the CAP protocol could not be completed pending expert consultation. Completion of the CAP protocol will then be performed following consultation.

B. Tissue Allocation
The majority of resection specimens are post-therapy and therefore the below submission recommendations may not be applicable. The submission recommendations are for pre-treated specimens.

Molecular testing is crucial for accurate risk stratification and clinical decision making. In addition to the tissue taken for histologic examination, the International Neuroblastoma Pathology Committee recommends sampling a neuroblastic surgical specimen for biologic studies as follows:

When handling an excisional biopsy specimen, sections should be obtained from central and peripheral areas of the tumor according to common guidelines (at least 1 tumor section per centimeter in the longest dimension). All grossly visible nodules or hemorrhagic foci in the tumor should be individually sampled.

Submission of Tissue from These Samples
First priority should always be given to formalin-fixed tissue paraffin embedded (FFPE) for morphologic evaluation. Special studies (e.g., fluorescence in situ hybridization for MYCN status, SNP array, next generation sequencing, and/or ploidy analysis) are critical to the molecular workup of neuroblastoma and second priority should be aliquoting at least 1 g of viable tumor tissue (1cm³ from an open biopsy or 10-50 needle cores, depending on gauge and length).

The International Neuroblastoma Pathology Committee recommends this additional material be allocated as follows:

1. MYCN analysis: tumor tissue in culture media, touch preps, or snap-frozen depending on the methodology used.
2. Ploidy and additional molecular genetic studies (LOH for 1p and 11q, segmental chromosomal aberrations): tumor tissue in culture media or snap-frozen depending on the methodology used.
3. Remainder snap-frozen in liquid nitrogen and stored at –80°C for other molecular testing (see Note I, below). The above recommendations are applicable when the entire or a large proportion of the tumor is resected, or when 1 or more large biopsy specimens are available. If the amount of tumor tissue is restricted, morphologic diagnosis is the prime consideration. Imprints (for FISH study of MYCN) should always be made from fresh tumor tissue.

References

C. Tumor Site
The abdomen is the most common primary site of neuroblastoma, with more than 70% of tumors arising in the adrenal glands or in the paravertebral sympathetic chains. Patients with abdominal primaries may present with abdominal distension with or without abdominal pain. The posterior mediastinum is the second most common primary site; respiratory symptoms may prompt evaluation or masses may be noted incidentally. Cervical neuroblastoma typically presents as a mass with or without Horner syndrome (oculosympathetic palsy). All neuroblastomas, regardless of biologic risk, can extend along radicular
nerves, through spinal foramina, and into the epidural space, forming a dumbbell-shaped mass. Similarly, primary tumors in the pelvis may present with constipation or urinary symptoms, including dysuria, infection, flank pain, or urinary retention.

**D. Treated Tumors**

Neuroblastic tumors treated with chemotherapy typically show 1 of 3 responses: (1) maturation of the neuroblastic component, with increased Schwannian stromal content and a shift along the spectrum from neuroblastoma towards ganglieneuroma; (2) necrosis of tumor cells with areas of hemorrhage (including hemosiderin-laden macrophages), calcifications, and fibrosis/stromal overgrowth; or (3) no significant effect. The International Neuroblastoma Pathology Classification (INPC) **DOES NOT** apply to treated tumors and should not be used. Rather, a diagnosis of “neuroblastoma (or whatever the original classification was) with treatment effect” should be rendered, and the histologic features enumerated. Any residual foci of undifferentiated or poorly differentiated neuroblasts should be commented upon; the percentage of viable tumor can be estimated, although the clinical significance of this value is dubious.

Important note: Once the International Neuroblastoma Pathology Classification (INPC) has been applied to a tumor based on pretreatment pathologic evaluation, the favorable/unfavorable histology designation never changes, regardless of posttreatment clinical or pathologic changes.

**E. Histopathologic Type & Immunohistochemistry**

It is recommended that the International Neuroblastoma Classification described below, be used when reporting untreated tumor samples.

There are 4 specific categories in this group of tumors:

- Neuroblastoma (Schwannian stroma-poor)
- Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)
- Ganglieneuroma (Schwannian stroma-dominant)
- Ganglioneuroblastoma, nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor)

**Neuroblastoma (Schwannian Stroma-Poor) Category**

Microscopically, tumors in the neuroblastoma category are composed of neuroblastic cells that form groups or nests separated by delicate, often incomplete stromal septa without or with limited Schwannian proliferation (comprising less than 50% of the tumor). See Note F for more details on neuroblastic differentiation.

**Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich) Category**

Ganglioneuromatous component (please see below) of the tumor exceeds 50%. Neuroblastic component is present in an intermixed or randomly distributed pattern of microscopic nests. In those microscopic nests, tumor cells are in various stages of differentiation (often predominantly differentiating neuroblasts) with clearly recognizable naked neuritic processes around their cytoplasm (neuropil). Histologically, tumors in this category are one step behind the final stage of complete maturation toward ganglieneuroma. Macroscopic hemorrhagic/necrotic nodules are absent.

**Ganglieneuroma (Schwannian Stroma-Dominant) Category**

In this category, Schwannian stroma is predominant and maturing and mature ganglion cells are individually distributed or forming small clusters in the stroma. Completely mature ganglion cells are covered with satellite cells. Please note, in order to avoid confusion here, ganglion cells are distinguished from differentiating neuroblasts based on the presence or absence of naked neuritic processes (neuropil) detected by H&E-stained section around their cytoplasm. Neuritic processes of the differentiating
neuroblasts are still segmentally naked and not completely covered by Schwannian stromal cells. Where no naked neuritic processes are identifiable around the ganglion cells, since they are immediately and completely incorporated in the cytoplasm of Schwannian stromal cells. In summary, no microscopic foci of neuroblastic cells with detectable naked neuritic processes are found in tumors of the Ganglioneuroma category.

Ganglioneuroblastoma, Nodular (Composite, Schwannian Stroma-Rich/Stroma-Dominant and Stroma-Poor) Category
Tumors in this category are composed of multiple clones: 1 or more Neuroblastoma (Schwannian stroma-poor) nodules set within a background of Ganglioneuroblastoma, Intermixed (Schwannian stroma-rich), or Ganglioneuroma (Schwannian stroma-dominant) tissue. Please note that Neuroblastoma nodules are often hemorrhagic and/or necrotic, and Ganglioneuroblastoma, Intermixed/Ganglioneuroma component is tan-yellow and solid.

Neuroblastic Tumor, Unclassifiable
Neuroblastic cells evident; sample insufficient for categorization into 1 of the 4 basic categories. A small biopsy taken from a large tumor can result in this designation.

Post-Chemotherapy Specimens
Neuroblastomas may undergo extensive morphologic changes post-chemotherapy. For this reason, biopsies or resections of treated tumors should be simply referred to as “neuroblastoma with treatment effect” or “treated neuroblastoma”, with reference to the original diagnostic subtype, if known. Similarly, recurrent disease should not be re-classified.

Immunohistochemistry
Recent advancements in immunohistochemistry have aided in the diagnosis of challenging cases, particularly undifferentiated neuroblastoma. Phox2B protein, positive for neural crest tumors of neuronal and neuroendocrine differentiation, is now recognized as the most sensitive and specific immunohistochemical marker for neuroblastoma,4,5 Please note that Phox2B is positive for all peripheral neuroblastic tumors as well as paraganglioma/pheochromocytoma. Thus, Phox2B is not entirely specific, but immensely helpful adjunct for neuroblastoma diagnosis when dealing with pediatric small round cell tumors (Ewing sarcoma, alveolar rhabdomyosarcoma, among others). Phox2B may also be employed to aid in identification of metastatic neuroblastoma in bone marrow or other sites.5

Other less specific immunohistochemical markers may also be frequently positive in neuroblastoma, to include PGP9.5, CD56 and NB84. Neuroblasts are also typically positive for synaptophysin and neuron-specific enolase, although these are less specific. Schwann cells are positive for S100 protein. Undifferentiated neuroblastoma cells may, on rare occasions, express vimentin.

References


F. Degree of Neuroblastic Differentiation

Degree of neuroblastic differentiation should be applied to the initial diagnostic material (e.g., pre-chemotherapy). All tumors in the Neuroblastoma (Schwannian stroma-poor) category and neuroblastic components of the Ganglioneuroblastoma, Nodular (Composite, Schwannian stroma-rich/stroma-dominant and stroma-poor) category are further classified into 1 of 3 subtypes.¹

Undifferentiated Subtype

No neuritic process formation by tumor cells. No tumor cell differentiation to include no formation of rosettes or other secondary structures; diagnosis relies heavily on ancillary techniques, such as immunohistochemistry and/or molecular/cytogenetic analysis. Some tumors in this subtype show a “starry-sky” appearance.

Poorly Differentiated Subtype

Neuritic process formation by tumor cells evident in background; less than 5% of tumor cells show features of differentiating neuroblasts with synchronous differentiation of the nucleus (enlarged, vesicular with a single prominent nucleolus) and the cytoplasm (conspicuous, eosinophilic or amphophilic, and twice the diameter of the nucleus).

Differentiating Subtype

Greater than 5% of tumor cells show the appearance of differentiating neuroblasts; active neuritic process production by the tumor cells; some tumors can show substantial Schwannian stromal development, frequently at their periphery, and a transition zone between neuroblastomatous and ganglioneuromatous regions can develop (although this zone lacks well-defined borders and comprises less than 50% of the tumor).

References


G. Mitotic-Karyorrhectic Index

The mitotic-karyorrhectic index (MKI)² is the number of mitotic figures and karyorrhectic nuclei per 5000 neuroblastic cells. At initial diagnosis, it is a useful prognostic indicator for tumors in the neuroblastoma (Schwannian stroma-poor) category, and should be determined as an average of all tumor sections available. The method described by Joshi et al.² can be used to calculate MKI without the need to count 5000 cells. In summary, cellular density is usually estimated under low power, and the tumor is classified as either a dense (1000-1500 cells per 400X high-power fields [HPFs])#, moderate (~800 tumor cells per HPF)¶, or mixed category (a mixed tumor has variable cellularity under different HPFs). Once categorized, random HPFs## are chosen to count mitotic and karyorrhectic cells. High-power fields on specimens in the mixed category are selected to be proportional to the cellular density in the specimen; for example, in a sample with 70% dense cellularity and 30% sparse cellularity, 70% of the HPF should be in dense areas and 30% in sparse areas. In highly cellular tumors, the MKI can be determined in 6 to 8 HPFs, whereas in tumors with low cellularity and prominent neuropil, 20 or more HPFs may be necessary.
Specimens are assigned to 1 of 3 prognostic categories:

(1) Low MKI:
Less than 100 mitotic and karyorrhectic cells/5000 tumor cells, or less than 2% of tumor consisting of mitotic and karyorrhectic cells

(2) Intermediate MKI:
100 to 200 mitotic and karyorrhectic cells/5000 tumor cells, or 2%-4% of tumor consisting of mitotic and karyorrhectic cells

(3) High MKI:
Greater than 200 mitotic and karyorrhectic cells/5000 tumor cells, or greater than 4% of tumor consisting of mitotic and karyorrhectic cells.

# Numbers of neuroblastic cells in each HPF (denominator for MKI determination) can vary, based on the type of microscope used (some practice is required for assessing the number of neuroblastic cells per HPF on a given microscope). The range of cells per HPF listed in parentheses in the above discussion are for a standard microscope setup with regular oculars. With a super-wide-field type of ocular, there may be an increased number of cells (1200 to 1500 cells per HPF in a dense category).

References

H. Prognostic Groups
The International Neuroblastoma Pathology Classification (INPC) uses age, neuroblastic maturation, Schwannian stromal content, and MKI as prognostic indicators. Unfavorable indicators include undifferentiated neuroblastoma (especially in older patients) and high MKI. An important revision was added in 2003. The original INPC classified all tumors in the category of ganglioneuroblastoma, nodular, as unfavorable. The revised INPC distinguishes 2 prognostic subsets in this category, favorable and unfavorable, by applying the same age-linked histopathology evaluation to the nodular (neuroblastoma) components (Table 1).

<table>
<thead>
<tr>
<th>Age</th>
<th>Favorable Histology Group</th>
<th>Unfavorable Histology Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td>Ganglioneuroma (Schwannian stroma-dominant)</td>
<td>Neuroblastoma (Schwannian stroma-poor)</td>
</tr>
<tr>
<td></td>
<td>Ganglioneuroblastoma, intermixed (Schwannian stroma-rich)</td>
<td>• undifferentiated and any mitotic-karyorrhectic index (MKI)</td>
</tr>
<tr>
<td>Less than 1.5 y</td>
<td>Neuroblastoma (Schwannian stroma-poor)</td>
<td>Neuroblastoma (Schwannian stroma-poor)</td>
</tr>
<tr>
<td></td>
<td>• poorly differentiated and low or intermediate MKI</td>
<td>• poorly differentiated and high MKI</td>
</tr>
<tr>
<td></td>
<td>• differentiating and low or</td>
<td>• differentiating and high MKI</td>
</tr>
</tbody>
</table>

Table 1. International Neuroblastoma Pathology Prognostic Classification (INPC)
intermediate MKI

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Neuroblastoma (Schwannian stroma-poor)</th>
<th>Ganglioneuroblastoma, nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor), favorable subset#</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5 y to less than 5 y</td>
<td>differentiating and low MKI</td>
<td></td>
</tr>
<tr>
<td>Greater than or equal to 5 y</td>
<td>differentiating and intermediate or high MKI</td>
<td></td>
</tr>
</tbody>
</table>

#The neuroblastic nodule(s) of the ganglioneuroblastoma, nodular subtype are graded with the INPC age-linked histopathology evaluation and based on that evaluation classified as favorable or unfavorable. For multinodular tumors, each nodule is graded separately, and the least favorable nodule determines the classification.

References


I. Staging

Given the increasing importance of pretreatment imaging characteristics, the pathologist is not required to report on staging for patients with neuroblastoma. The current INRG staging systems is described below and can be included in the comment section if desired.

**International Neuroblastoma Risk Group (INRG) Staging System (INRGSS)**

Recently, a new clinical staging system, the INRGSS, has been proposed and increasingly adopted. Unlike the INSS, which relies on postsurgical data, the INRGSS relies only on pretreatment imaging, patient age, and clinical extent of disease. The INRGSS can be summarized as localized disease (stage L1), regional disease (stage L2), metastatic disease (stage L3), and “special stage” (stage MS, similar to the INSS stage 4S). However, this schema relies heavily on image-defined risk factors* and may be difficult for pathologists to implement.

Stage L1
- Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment

Stage L2
- Locoregional tumor with presence of 1 or more image-defined risk factors

Stage M
- Distant metastatic disease (except stage MS)

Stage MS
- Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow with minimal marrow involvement as described in stage 4S, above.

*Image-Defined Risk Factors
Ipsilateral tumor extension within 2 body compartments
  • Neck-chest, chest-abdomen, abdomen-pelvis

Neck
  • Tumor encasing carotid and/or vertebral artery and/or internal jugular vein
  • Tumor extending to base of skull
  • Tumor compressing the trachea

Cervico-thoracic junction
  • Tumor encasing brachial plexus roots
  • Tumor encasing subclavian vessels and/or vertebral and/or carotid artery
  • Tumor compressing the trachea

Thorax
  • Tumor encasing the aorta and/or major branches
  • Tumor compressing the trachea and/or principal bronchi
  • Lower mediastinal tumor, infiltrating the costo-vertebral junction between T9 and T12

Thoraco-abdominal
  • Tumor encasing the aorta and/or vena cava

Abdomen/pelvis
  • Tumor infiltrating the porta hepatis and/or the hepatoduodenal ligament
  • Tumor encasing branches of the superior mesenteric artery at the mesenteric root
  • Tumor encasing the origin of the coeliac axis, and/or of the superior mesenteric artery
  • Tumor invading 1 or both renal pedicles
  • Tumor encasing the aorta and/or vena cava
  • Tumor encasing the iliac vessels
  • Pelvic tumor crossing the sciatic notch
  • Intraspinal tumor extension whatever the location provided that: More than one-third of the spinal canal in the axial plane is invaded and/or the perimedullary leptomeningeal spaces are not visible and/or the spinal cord signal is abnormal

Infiltration of adjacent organs/structures
  • Pericardium, diaphragm, kidney, liver, duodeno-pancreatic block, and mesentery
  • Conditions to be recorded, but not considered image-defined risk factors

Multifocal primary tumors
  • Pleural effusion, with or without malignant cells
  • Ascites, with or without malignant cells

Risk Groups
Risk group assessment can be defined by clinical and biological variables. The risk-grouping scheme for clinical trials of the Children’s Oncology Group Neuroblastoma Studies was based on the combination of INRGSS clinical stage, age at diagnosis, MYCN status, histopathology classification, loss of heterozygosity at 1p or 11q and DNA index. (Table 2).

### Table 2. Risk Grouping Scheme for the International Neuroblastoma Risk Group (INRG) System

<table>
<thead>
<tr>
<th>INRG Stage</th>
<th>Age</th>
<th>Histologic Category</th>
<th>MYCN</th>
<th>Unbalanced 11q aberration</th>
<th>Ploidy</th>
<th>Pretreatment Risk Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1</td>
<td></td>
<td>GN maturing</td>
<td>NA</td>
<td></td>
<td></td>
<td>A Very Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GN maturing</td>
<td>NA</td>
<td></td>
<td></td>
<td>B Very Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GNB intermixed</td>
<td>NA</td>
<td></td>
<td></td>
<td>I Intermediate</td>
</tr>
<tr>
<td>Any, except GN maturing or GNB intermixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

15
### J. Clinical Associations with Pathological Findings

The opsoclonus-myoclonus ataxia syndrome (OMAS) is the most common example of a paraneoplastic manifestation of neuroblastoma. This is thought to occur due to cross-reactivity between antineuroblastoma antibodies and the Purkinje cells of the cerebellum. In keeping with the proposed immune mechanism, neuroblastic tumors in patients with OMAS near-always have diffuse and extensive lymphoid infiltration with lymphoid follicles. About three-quarters of OMAS-associated tumors are neuroblastoma, with ganglioneuroblastoma and ganglioneuroma less common; nonetheless, only about 50% of OMAS cases occur in patients with a known or discoverable tumor, and only 2-4% of neuroblastic tumors are associated with OMAS. A note should be made in the “Additional Pathologic Findings” section when a tumor has lymphocytes and lymphoid aggregates occupying more than half of any high-powered field. Although patients with OMAS usually have an excellent prognosis with respect to their neuroblastoma, many patients with OMAS may have persistent neurologic, developmental or behavioral issues despite complete tumor resection.

Several rarer paraneoplastic syndromes can be associated with neuroblastoma. ROHHAD syndrome (rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation) is usually associated with ganglioneuromas, and less frequently with other neuroblastic tumors. This syndrome
may be associated with lymphocytic infiltration of the hypothalamus. Intriguingly, there is significant clinical overlap between ROHHAD and congenital central hypoventilation, the latter of which has pathogenic PHOX2B mutations.\(^4\)

Tumor secretion of excess vasoactive intestinal peptide (VIP) can cause profuse watery diarrhea with resultant electrolyte abnormalities; this too may improve with tumor resection. Histologically, VIP-excreting tumors tend to demonstrate a more well-differentiated phenotype (differentiating neuroblastoma or ganglioneuroblastoma) and have a better prognosis.\(^5,6\)

References


K. Special Studies

Imaging

Cross-sectional imaging (computed tomography or magnetic resonance imaging) provides important information about the primary tumor, including location, vascular encasement status, and the status of regional lymph nodes. Hepatic and bony metastases can be visualized, as can less common sites of disease. MRI can be particularly helpful in delineating the relationship of tumor to structures near the spine.

Nuclear medicine imaging is important for treatment planning and assessment of extent of disease. Approximately 90% of neuroblastomas will take up meta-iodobenzylguanidine (MIBG), and therefore MIBG whole body scans can be helpful in delineating sites of metastatic disease, particularly disease involving bone and bone marrow. For patients with neuroblastoma whose disease is MIBG non-avid, fluoro-deoxyglucose-positron emission tomography (FDG-PET) imaging is used for detection of metastatic lesions.
Urinary catecholamines
Urinary catecholamine secretion is increased in neuroblastoma and is useful as a confirmatory diagnostic marker. Vanillylmandelic acid (VMA) and homovanillic acid (HVA) are the 2 catecholamine metabolites commonly measured via high-performance liquid chromatography. Due to concerns regarding the sensitivity and specificity of urinary catecholamines for assessment of disease status, measurement of HVA and VMA are no longer included as components of response assessment according to the International Neuroblastoma Response Criteria.

References

L. Molecular Classification/Genetics
**MYCN Amplification**
The most prognostically relevant genetic alteration in neuroblastoma is MYCN amplification. MYCN gene amplification is associated with high-risk neuroblastic tumors and poor patient prognosis. MYCN is a proto-oncogene located on the short arm of chromosome 2, the amplification of which leads to inhibiting cellular differentiation and promoting cellular proliferation and apoptosis/karyorrhexis. Not surprisingly, amplification is associated with undifferentiated and poorly differentiated neuroblastomas with a high mitotic-karyorrhectic index.1

MYCN overexpression usually occurs by gene amplification in 1 or both of the following ways: (1) gene duplication adjacent to the usual locus on 2p, forming homogeneously staining regions (HSRs) seen on chromosomal banding patterns; and (2) formation of double minutes, small, circular extrachromosomal fragments of DNA that harbor copies of the MYCN gene and are replicated during mitosis. These mechanisms can occur individually or simultaneously in a given tumor cell.

The MYCN status of a given neuroblastic tumor can be determined by FISH within a relatively short period of time after the surgery/biopsy using touch preparation slides or formalin-fixed, paraffin-embedded sections (Note B). A double-staining procedure is required in order to compare the number of chromosome 2 and MYCN signals in the same tumor nuclei. Additional MYCN signals associated with a similar increase in the number of chromosome 2 signals does not represent MYCN amplification. MYCN status is defined as “amplified” when MYCN signals exceed chromosome 2 signals by 3 times or more in the given tumor cell nuclei. The prognostic significance of tumors showing increased MYCN signals, but not more than 3 times that of chromosome 2 signals (MYCN gain), is yet to be determined.

Recent studies have identified a subset of neuroblastic tumors with “discordance” between the genotype (MYCN amplification status) and the phenotype (differentiation, MKI, and histologic classification).4 In cases with amplification of the MYCN gene but favorable histologic features (differentiating neuroblasts and/or low-intermediate MKI), the cells do not produce active N-myc protein and lack the classic “bulls eye” nucleoli. In cases that lack MYCN amplification but have unfavorable histologic features (undifferentiated neuroblasts and/or high MKI), C-myc protein is often being expressed instead.3

MYCN amplification is also correlated with advanced-stage tumors often having chromosome 1p deletions, especially del 1p36.3.4 The deletion of 14q has also been shown to be unfavorable, as have loss of 11q and gain of 17q.3
**ALK Mutation and Amplification**

Studies have demonstrated mutations in the anaplastic lymphoma kinase (ALK) gene in a subset of neuroblastic tumors, as well as in the germline of patients with a familial predisposition to this disease. Single base missense mutations within the kinase domain of ALK occur in approximately 8% to 10% of neuroblastoma, and another approximate 2% have ALK gene amplification. These ALK aberrations are associated with higher risk and worse prognosis. While ALK immunohistochemistry is commonly performed in pathology laboratories to demonstrate ALK protein expression which correlates with ALK fusion status in tumors such as anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumor (IMT), ALK immunohistochemistry does NOT correlate with ALK mutational status in neuroblastic tumors. Therefore in the setting of treatment-refractory patients who might be candidates for tyrosine kinase inhibitors, ALK gene sequencing (especially of the kinase regions and mutational hotspots) is needed for mutational analysis; FISH may be employed to evaluate for gene amplification.

**DNA Index**

Determination of DNA index by flow cytometry is also important; however, a minimum of 100 mg and preferably 1g of fresh tumor is typically required for this purpose (Note B). A DNA index near diploid/tetraploid is unfavorable, while hyperdiploid (near triploid) tumors have a better prognosis. However, the prognostic effects of DNA index are reported to be limited to those patients diagnosed at younger than 1 year of age.

**Segmental Chromosomal Aberrations**

Segmental chromosomal aberrations (SCA; especially 1p deletion, 11q deletion, and/or 17q gain) are typically associated with high-risk tumors, whereas alterations in the numbers of whole chromosomes are associated with lower risk tumors. Most labs assess the presence of SCA using next generation sequencing assays or variations of microarray techniques (see Note B). Risk group assignment may be affected by ploidy status.

**Other**

Additional genetic abnormalities may have clinicopathologic significance in neuroblastic tumors but are not yet routinely assessed. One important category are genes involved in the telomere maintenance or alternate lengthening of telomeres (ALT) pathway, as abnormal lengthening of telomeres can prolong tumor cell survival. Mutations in the alpha-thalassemia/mental retardation X-linked syndrome (ATRX) gene, a member of the SWI/SNF family of chromatin remodeling proteins, are only found in 2%-3% of all neuroblastic tumors overall but occur in the vast majority of high-stage tumors in older children and adolescents (whereas congenital and infantile tumors only exceedingly rarely have them). The ATRX gene product plays a role in telomere maintenance, and tumor cells with mutated ATRX have longer-than-usual telomeres, prolonging their survival. Likewise, rearrangements in the telomere reverse transcriptase gene, TERT, are associated with high-risk neuroblastic tumors, and occur exclusively of MYCN amplification and ATRX mutations. In fact, aberrations of MYCN, ATRX, and TERT appear to represent three separate genetic categories of neuroblastoma with minimal overlap but a shared poor prognosis.

Neuroblastic tumors are usually wild-type for TP53, although p53 activity may be altered through other mechanisms. PHOX2B mutations are frequently seen in familial neuroblastomas, but only rarely in sporadic tumors.

**References**


